| Metric | FY 2026 | FY 2025 |
|---|---|---|
| Revenue | 2.3 | 2.2 |
| Gross profit | 1.3 | 1.3 |
| Net income | -2.5 | -2.4 |
| EPS (diluted, $ a share) | $-0.02 | $-0.02 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +5.3% |
|---|---|
| Gross margin | 57.2% |
| Operating margin | -89.9% |
10-K filed with the SEC, OTC: PURE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Pure Bioscience, Inc.: key numbers
- Share price
- $0.0600Close, Nov 16
- Market cap
- $8.41M
- Shares outstanding
- 140.2MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Miscellaneous Chemical ProductsSIC 2890
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Pure Bioscience, Inc.
All →Pure Bioscience Financial Results
PURE Bioscience reported financial results for the fiscal year ended July 31, 2026, with net product sales increasing 5% to $2.3 million. The company posted a net loss of $2.5 million, or $0.02 per share, as growth in its end-user network was offset by a challenging macro environment and disruptions in the food industry.
- Term
- FY2026
“We are up year-over-year despite being a challenging year, with the macro environment causing increased expenses and foodborne outbreaks severely disrupting the food industry. Although our growth didn’t meet expectations, our focus remains on reducing costs and converting more opportunities into revenue.”
Jeff Kitchell, Chief Executive Officer
Pure Bioscience Capital Raise of $555K
PURE Bioscience completed a private placement financing raising $555,000 through the issuance of 10,183,486 shares of common stock. The investment was made by board member Tom Y. Lee and his affiliates at a price of $0.0545 per share, with proceeds intended for research, development, and general working capital.
- Value
- $555K
- Counterparty
- Tom Y. Lee